177Lu-DOTATATE and177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy. For these patients, tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC. Nevertheless, these therapies are related with substantial si...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
| Series: | World Journal of Nuclear Medicine |
| Subjects: | |
| Online Access: | http://www.wjnm.org/article.asp?issn=1450-1147;year=2019;volume=18;issue=4;spage=406;epage=408;aulast=Assadi |